More about
Dapagliflozin
News
January 23, 2025
2 min read
Save
ACC announces lineup of 2025 Scientific Session late-breakers
News
October 22, 2024
2 min read
Save
Sodium-glucose inhibitor use in PAH may have mortality benefit
News
August 15, 2024
4 min read
Save
Medicare announces price cuts for 10 drugs in first round of drug price negotiations
News
June 19, 2024
2 min read
Save
Top in endocrinology: New OTC glucose monitors; exposure to endocrine-disrupting chemicals
News
June 13, 2024
1 min read
Save
FDA approves dapagliflozin for children and adolescents with type 2 diabetes
Part of the Healio Network
Sodium-Glucose Transporter 2 (SGLT2) Inhibitors Topic Review
As a class, sodium–glucose transporter 2 inhibitors are novel drugs initially developed for glycemic control in patients with type 2 diabetes. [Cowie MR, et al. Nat Rev Cardiol. 2020;1a]
News
April 01, 2024
3 min read
Save
Dapagliflozin reduces diuretic doses, daily uptitrations and hospital stay for acute HF
News
January 24, 2024
2 min read
Save
Mortality benefit derived from SGLT2 inhibition could extend to HF with improved EF
News
January 02, 2024
3 min read
Save
Top cardiology news in 2023: A year of firsts for CVD treatments, procedures, devices
News
November 12, 2023
3 min read
Save